SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

April 21, 2014 08:30 ET

OmniComm Systems® Announces New Release of TrialOne®

Numerous Usability and Functionality Enhancements Increase Phase I Clinic Productivity

FORT LAUDERDALE, FL--(Marketwired - Apr 21, 2014) -  OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of clinical data management solutions for clinical trials, announced the general availability of TrialOne version 4.3. TrialOne is a browser-based, mobile, clinic automation solution designed specifically for early-phase research that facilitates subject recruitment, source data capture, sample tracking, data management and reporting. TrialOne offers time-based data entry and automates many data collection activities via its ability to both print and scan barcodes, as well as to integrate directly with medical monitoring and laboratory equipment. Furthermore, TrialOne's import and export features provide integration with laboratory information management systems for lab orders and results processing.

TrialOne version 4.3 includes numerous productivity and functionality enhancements that drive efficiencies and reduces costs through faster volunteer recruitment, flexible screening questionnaires, direct data capture, work flow automation and modern data processing.

Enhancements to TrialOne include the following.

  • Comprehensive integration with bedside patient monitoring, telemetry and clinical devices with enhanced ability to send electrocardiography (ECG) orders to devices such as Mortara Surveyor™ Central System, Seca scales, and Sartorius laboratory balances.
  • Enable open-label clinical study design allowing researchers and participants to know which treatment is being administered.
  • Ability to read ECG tracings in real-time enabling clinic staff to effectively respond to research participants in a timely fashion.
  • Study teams receive electronic notification alerts of research participant's adverse experiences allowing them to take appropriate clinical action and medical intervention.
  • Enhancements in handling treatment blinding allows researchers to effectively track drugs per research participant in adherence to clinical plan and dosages ensuring adherence to clinical protocols where multiple drugs are ordered.
  • TrialOne now supports open-label (no blinding), single-blinding (participant blinded), double-blinding (floor staff blinded), and triple-blinding (data extract blinded).

"TrialOne continues to set the standard for the automation of early phase clinics," stated Randy Smith, OmniComm's CTO and TrialOne Group Executive Sponsor. "The 4.3 release builds on our successful TrialOne suite providing a platform for future planned enhancements".

Supporting Information

TrialOne

Seoul National University Hospital Signs Five Year Agreement with OmniComm Systems® TrialOne® for Clinical Research Automation

About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.